MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 F

EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability 30.01.2024 / 08:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Mu...

Related Keywords

United States ,Planegg ,Bayern ,Germany ,Canada ,Massachusetts ,Boston ,Eamonn Nolan ,Julia Neugebauer ,Jean Paul Kress ,Thomas Biegi ,Xencor Inc ,Drug Administration ,Twitter ,Corporate Affairs ,European Medicines Agency ,Exchange Commission ,Nasdaq ,Lymphoma Society ,Corporate Communications Investor Relations ,Distribution Services ,Linkedin ,Constellation Pharmaceuticals Inc ,Sys Reports Preliminary ,Gross Margin ,Reduces Financial Liability ,Product Sales ,Reduces Financial ,Chief Executive Officer ,Morphosy Phase ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Prescribing Information ,Morphosy Annual Report ,Vice President ,Global Investor ,Corporate Communications ,Corporate News ,Regulatory Announcements ,